Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 714 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07405372Recruiting
IDH mutation PET/MRI scan for brain tumors
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07397728Recruiting
TREX1 gene changes in lupus with skin rashes
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Qina, South ValleyAges 18–60 - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT05818319Recruiting
Tracking kidney urine effects after a short pause in CF therapy
This study checks how a common cystic fibrosis (CF) medicine affects urine markers after briefly stopping it and then restarting. The goal is to better understand whether the treatment shift changes kidney-related signals in people with CF.
Aarhus C, Central JutlandAges 18 years+ - NCT06158399RecruitingPhase 2
Combination therapy for a specific type of lymphoma
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Xiamen, FujianAges 18–70 - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Scottsdale, ArizonaAges 18 years+ - NCT04251078Recruiting
Blood tests to track mutations in lower-risk MDS
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
Badalona, BarcelonaAges 18 years+ - NCT07375316RecruitingPhase 2
Combination therapy for EGFR-mutated lung cancer with lingering ctDNA
This trial tests if adding sacituzumab tirumotecan to osimertinib works better than osimertinib alone for advanced lung cancer that still shows cancer DNA (ctDNA) in the blood after initial osimertinib treatment.
Guangzhou, GuangdongAges 18 years+ - NCT07374913Recruiting
Study of COL4A1 and COL4A2 gene mutations
This study looks at people with a mutation in the COL4A1 or COL4A2 genes, which can cause problems in small blood vessels throughout the body. It aims to learn more about the condition and may also include family members who carry the mutation or who can serve as healthy controls.
Florence, FIAges Any age - NCT07379476RecruitingPhase 2
Targeted treatment for remaining spots in EGFR lung cancer
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
Hong KongAges 18 years+ - NCT07371104RecruitingPhase 1
Study of DWZ2501 in advanced BRCA ovarian cancer on olaparib
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
Seoul, Jongno-guAges 19 years+ - NCT04590664RecruitingPhase 1/Phase 2
Verteporfin for recurrent EGFR-mutant glioblastoma
This trial tests verteporfin (Visudyne), given through a vein, for recurrent glioblastoma that has an EGFR mutation or increased EGFR. It aims to shrink or slow the tumor after standard treatment has already been tried.
Atlanta, GeorgiaAges 18 years+ - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07369596Recruiting
Chemotherapy doses and survival in older lung cancer patients
This study looks at how lowering chemotherapy doses affects survival in older patients with advanced lung cancer who do not have certain genetic mutations. It may help doctors understand the best way to treat this group.
Hong KongAges 65 years+ - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+ - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07356544Recruiting
HER2 mutations in advanced non-small cell lung cancer
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
Bari, BAAges 18 years+ - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT06643000Recruiting
High-dose furmonertinib combo for EGFR lung cancer with brain lining spread
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Zhengzhou, HenanAges 18 years+ - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 714 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.